ENV, HIV1: GP41
Protein in Human immunodeficiency virus 1 that 1 drug acts on.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on ENV, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Albuvirtide | Phase 3 | Frontier Biotechnologies Inc. | Protein or peptide | InhibitorGP41 inhibitor | 2 |
| Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma | Albuvirtide | Not applicable | Recruiting | Shanghai Public Health Clinical Center | Jul 27, 2026 |
| Research on the Psychological Status of Patients With HIV-1 Infection | Albuvirtide | — | Not yet recruiting | Shanxi Bethune Hospital | Jul 23, 2025 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3559676, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets